Skip to main content

MDS Acquires Blueshift Biotechnologies

NEW YORK (GenomeWeb News) – MDS said today that its MDS Analytical Technologies unit has acquired cell imaging products firm Blueshift Biotechnologies for $13 million.
 
Sunnyvale, Calif.-based Blueshift makes the IsoCyte benchtop instrument, which performs rapid image analysis of large populations of cells in a microtiter plate whole-well format. According to Toronto-based MDS, Blueshift has placed 14 of the IsoCyte instruments with academic, biotech, and pharmaceutical customers.
 
“This acquisition fills a gap in our current product portfolio, allowing us to offer our pharmaceutical research customers fast and simple cellular analysis with a line of instrumentation that images the whole well at true high throughput screening rates,” Andy Boorn, president of MDS Analytcial Technologies, said in a statement.
 
The firms did not disclose Blueshift’s annual revenues.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.